Triglycerides revisited: is hypertriglyceridaemia a necessary therapeutic target in cardiovascular disease?
European Heart Journal - Cardiovascular Pharmacotherapy · 20.09.2023 · 9 (6) · 570-582
DOI: 10.1093/ehjcvp/pvad044 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift European Heart Journal - Cardiovascular Pharmacotherapy, online erschienen am 16.06.2023. Verfasst von Heinz Drexel und 10 weiteren Autor:innen. Beteiligte Einrichtung: Vorarlberg Institute for Vascular Investigation and Treatment (VIVIT), Vorarlberg, Austria. Hauptthemen laut MEDLINE: Cardiovascular Diseases, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Hypertriglyceridemia, Atherosclerosis. Die Arbeit wurde bisher 28-mal zitiert (Crossref) und nennt 80 Literaturangaben. Gefördert von: National Hospital Organization.
Abstract (Originalsprache)
Despite the atherosclerotic cardiovascular disease (ASCVD) risk reduction achieved by low-density lipoprotein cholesterol (LDL-C) lowering therapy, residual ASCVD risk still exists. Previous epidemiological studies have suggested high plasma triglyceride (TG) levels as a risk factor or risk marker for ASCVD independent of LDL-C levels. In this review, we highlighted the underlying pathophysiology of hypertriglyceridaemia, the mechanistic action of therapeutic agents, the interpretation of conflicting results on recent clinical trials, and the present options for primary and secondary prevention. The benefits of fibrates-induced reduction in TG and increase in high-density lipoprotein cholesterol might outweigh the disadvantages of increasing LDL-C levels in primary prevention. In secondary CVD prevention, using eicosapentaenoic acid without docosahexaenoic acid, in addition to statins, will be beneficial. This comprehensive review may prove useful for the development of novel approaches that target hypertriglyceridaemia in future.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Vorarlberg Institute for Vascular Investigation and Treatment (VIVIT), Vorarlberg, Austria.
- Department of Pharmacology and Toxicology, School of Medicine, Universidad Complutense, Instituto De Investigación Sanitaria Gregorio Marañón, Madrid, Spain.
- Molecular and Clinical Sciences Research Institute, St George's, University of London, London, UK.
- Ruth and Bruce Rappaport School of Medicine, Technion-Israel Institute of Technology, Haifa, Israel.
- Medical Central Laboratories, Academic Teaching Hospital Feldkirch, Feldkirch, Austria.
- Institute of Pharmacology, Faculty of Medicine, University Duisburg-Essen, Essen, Germany.
ORCID-Profile: Heinz Drexel, Juan Carlos Kaski, Dobromir Dobrev, Koji Hasegawa
Förderung
- National Hospital Organization
Zitieren
APA
Drexel, H., Tamargo, J., Kaski, J. C., Lewis, B. S., Saely, C. H., Fraunberger, P., Dobrev, D., Komiyama, M., Plattner, T., Agewall, S., & Hasegawa, K. (2023). Triglycerides revisited: is hypertriglyceridaemia a necessary therapeutic target in cardiovascular disease?. European Heart Journal - Cardiovascular Pharmacotherapy, 9(6), 570-582. https://doi.org/10.1093/ehjcvp/pvad044
Vancouver
Drexel H, Tamargo J, Kaski JC, Lewis BS, Saely CH, Fraunberger P, et al. Triglycerides revisited: is hypertriglyceridaemia a necessary therapeutic target in cardiovascular disease?. European Heart Journal - Cardiovascular Pharmacotherapy. 2023;9(6):570-582. doi:10.1093/ehjcvp/pvad044
BibTeX
@article{Drexel2023,
author = {Drexel, Heinz and Tamargo, Juan and Kaski, Juan Carlos and Lewis, Basil S and Saely, Christoph H and Fraunberger, Peter and Dobrev, Dobromir and Komiyama, Maki and Plattner, Thomas and Agewall, Stefan and Hasegawa, Koji},
title = {Triglycerides revisited: is hypertriglyceridaemia a necessary therapeutic target in cardiovascular disease?},
journal = {European Heart Journal - Cardiovascular Pharmacotherapy},
year = {2023},
volume = {9},
number = {6},
pages = {570--582},
doi = {10.1093/ehjcvp/pvad044}
}
EUVIMED